MedTrace Logo

Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

NCT00372073 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2021-12-22

No results posted yet for this study

Summary

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Conditions

Interventions

DRUG

seliciclib

1200 mg bid x 3 days every 2 weeks

DRUG

placebo

1200 mg bid x 3 days every 2 weeks

Sponsors & Collaborators

  • Cyclacel Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Chandra Belani, M.D. · Milton S. Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-09
Primary Completion
2009-03-03
Completion
2009-04-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372073 on ClinicalTrials.gov